Increased expression of cyclin-dependent kinase inhibitor 2 (CDKN2A) gene product p16(INK4A) in ovarian cancer is associated with progression and unfavourable prognosis

International Journal of Cancer

Volumn 74, Issue 1, 1997, Pages 57-63

  Dong, Ying ^a   Walsh, Michael D ^a   Mcguckin, Michael A ^a   Gabrielli, Brian G ^b   Cummings, Margaret C ^a   Wright, R Gordon ^a   Hurst, Terry ^a   Khoo, Soo Keat ^a   Parsons, Peter G ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; TUMOR GROWTH;

BLOTTING, WESTERN; CARRIER PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE PROGRESSION; FEMALE; GENES, TUMOR SUPPRESSOR; HELA CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0030955478     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970220)74:1<57::AID-IJC10>3.0.CO;2-F     Document Type: Article

References (26)

1. CAMPBELL, I.G., BEYNON, G., DAVIS, M. and ENGELFIELD, P., LOH and mutation analysis of CDKN2 in primary human ovarian cancers. Int. J. Cancer, 63, 222-225 (1995).
2. CHENEVIX-TRENCH, G., KERR, J., FRIEDLANDER, M.M., HURST, T., SANDERSON, B., COGLAN, M., WARD, B., LEARY, J. and KHOO, S.K., Homozygous deletions on the short arm of chromosome 9 in ovarian adenocarcinoma cell lines and loss of heterozygosity in sporadic tumours. Amer. J. hum. Genet., 55, 143-149 (1994).
3. GARIN-CHESA, P., OLD, L.J. and RETTIG, W.J., Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. nat. Acad. Sci. (Wash.), 87, 7235-7239 (1990).
4. INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55, 6006-6011 (1996).
5. HARRISON, R.F., REYNOLDS, G.M. and ROWLANDS, D.C., Immunohistochemical evidence for the expression of proliferating cell nuclear antigen (PCNA) by non-proliferating hepatocytes adjacent to metastatic tumours and in inflammatory conditions. J. Pathol., 171, 115-122 (1993).
6. HATTA, Y., HIRAMA, T., TAKEUCHI, S., LEE, E., PHAM, E., MILLER, C.W., STROHMEYER, T., WILCZYNSKI, S.P., MELAMED, S. and KOEFFLER, H.P., Alterations of the p16(MTS1) gene in testicular, ovarian, and endometrial malignancies. J. Urol., 154, 1954-1957 (1995).
7. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY, R.S. III, JOHNSON, B.E. and SKOLNICK, M.H., A cell cycle regulator potentially involved in genesis of many tumour types. Science, 264, 436-440 (1994).
8. KAPLAN, E.I. and MEIER, P., Nonparametric estimation from incomplete observations. J. Amer. Stat. Assoc., 53, 457-181 (1958).
9. KARLAN, B.Y., BALDWIN, R.L., CIRISANO, F.D., MAMULA, P.W., JONES, J. and LAGASSE, L.D., Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Gynecol. Oncol. 59, 67-74 (1995).
10. KOH, J., ENDERS, G.H., DYNLACHT, B.D. and HARLOW, E., Tumour-derived p16 alleles encoding proteins defective in cell-cycle inhibition. Nature (Lond.), 375, 506-560 (1995).
11. LUKAS, J., PARRY, D., AAGAARD, L., MANN, J.D., BARTKOVA, J., STRAUSS, M., TETERS, G. and BARTEK. J., Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375, 503-506 (1995).
12. NOBORI, T., MIURA, K., WU, D.J., LOUIS, A., TAKABAYASHI, K. and CARSON, D.A., Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368, 753-756 (1994).
13. OHTA, M., NAGAI, H., SHIMIZU, M., RASIO, D., BERD, D., MASTRANGELO, M., SINGH, A.D., SHIELDS, J.A., SHIELDS, C.L., CROCE, C.M. and HUEBNER, K., Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene. CDK4I, in melanoma. Cancer Res., 54, 5269-5272 (1994).
14. INK4 in human cancer. Proc. nat. Acad. Sci. (Wash.), 91, 11045-11049 (1994).
15. OSBORNE, R.J. and LEECH, V., Polymerase chain reaction allelotyping of human ovarian cancer. Brit. J. Cancer. 69, 429-438 (1994).
16. POLLOCK, P.M., PEARSON, J.V. and HAYWARD, N.K., Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer, 15, 77-88 (1996).
17. POLLOCK, P.M., YU, F., QIU, L., PARSONS, P.G. and HAYWARD, N.K., Evidence for UV induction of CDKN2 mutations in melanoma cell lines. Oncogene, 11, 663-668 (1995).
18. REED, J.A., LOGANZO, F. JR., SHEA, C.R., WALKER, G.J., FLORES, J.F., GLENDENING, J.M., BOGDANY, J.K., SHIEL, M.J., HALUSKA, F.G., FOUNTAIN, J.W. and ALBINO, A.P., Loss of expression of the 16/cyclin-dependent kinase inhibitor 2 tumour suppressor gene in melanocytic lesions correlates with invasive stage of tumour progression. Cancer Res., 55, 2713-2718 (1995).
19. RODABAUGH, K.J., BIGGS, R.B., QURESHI, J.A., BARRETT, A.J., WELCH, W.R., BELL, D.A., BERKOWITZ, R.S. and MOK, S.C., Detailed deletion mapping of chromosome 9p and p16 gene alterations in human borderline and invasive epithelial ovarian tumours. Oncogene. 11, 1259-1254 (1995).
20. SCHULTZ, D.C., VANDERVEER, L., BUETOW, K.H., BOENTE, M.P., OZOLS, R.R., HAMILTON, T.C. and GODWIN, A.K., Characterisation of chromosome 9 in human ovarian neoplasia identifies frequent genetic imbalance on 9q and rare alterations involving 9p, including CDKN2. Cancer Res., 55, 2150-2157 (1995).
21. SERRANO, M., HANNON, J.G. and BEACH, D., A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366, 704-707 (1993).
22. lnk4. Cancer Res., 54, 5816-5820 (1994).
23. VAN DEN HOOFF, A., Stromal involvement in malignant growth. Adv. Cancer Res., 50, 159-196 (1988).
24. 2 phase cell cycle delay. Cancer Res. (in press).
25. XIONG, Y., ZHANG, H. and BEACH, D., Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Develop., 7, 1572-1583 (1993).
26. YANG-FENG, T.L., HAN, H., CHEN, K.-C., LI, S.-B., CLAUD, B.E., CARCANGIR, M.L., CHAMBERS, S.K., CHAMBERS, J.T. and SCHWARTZ, P.E., Allelic loss in ovarian cancer. Int. J. Cancer. 54, 546-551 (1993).